{"classes":[{"categories":[{"measurements":[{"comment":"Too few events to estimate the 80% CIs","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"63.1"},{"comment":"No events therefore median and 80% CIs could not be estimated","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No events therefore median and 80% CIs could not be estimated","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Too few events to estimate the 80% CIs","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"60.8"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG004","lowerLimit":"8.1","upperLimit":"NA","value":"9.1"},{"comment":"Too few events to estimate the 80% CIs","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"19.2"},{"comment":"Too few events to estimate the 80% CIs","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"4.1"},{"comment":"Too few events to estimate the upper 80% CI","groupId":"OG007","lowerLimit":"6.7","upperLimit":"NA","value":"18.7"},{"comment":"Too few events to estimate the 80% CIs","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"2"}],"units":"Participants"}],"description":"DOR was defined as the time between the date of the first observation indicating an objective response as PR (or better) through to the subsequent date of disease progression as classified by the IMWG-URC for Multiple Myeloma or death or where applicable date of censoring. The median DOR was estimated using the Kaplan-Meier method.","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \\[MTD\\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment"},{"description":"Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG008","title":"Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment"}],"paramType":"MEDIAN","populationDescription":"The safety analysis set included all participants who received at least 1 dose of AMG 224.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years","title":"Duration of Response (DOR) According to IMWG-URC","type":"SECONDARY","unitOfMeasure":"months"}